Advanced Search

 

Study ID Status Title Patient Level Data
743830/002 Completed An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate Study Listed on ClinicalStudyDataRequest.com
743830/003 Completed An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate Study Listed on ClinicalStudyDataRequest.com
75 Completed Six-week, multicenter, double-blind, randomized, parallel comparison of the efficacy and safety of bupropion versus placebo in children with attention deficit disorder – Extensive searching has revealed that no clinical study report is available for this study.
759346/001 Completed A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccinationregimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age. Study Listed on ClinicalStudyDataRequest.com
759346/002 Completed Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects Study Listed on ClinicalStudyDataRequest.com
759346/007 Completed Demonstrate non-inferiority of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine Study Listed on ClinicalStudyDataRequest.com
759346/009 Completed Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological’s Hiberix vaccine, extemporaneously mixed with GSK Biological’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age Study Listed on ClinicalStudyDataRequest.com
759348/001 Completed A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life Study Listed on ClinicalStudyDataRequest.com
759348/002 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life
759348/003 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age. Study Listed on ClinicalStudyDataRequest.com
759348/007 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.
763310/001 Completed A phase I/II trial of an investigational vaccination regimen in infants.
763674/001 Completed A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
763674/002 Completed A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
773812/007 Completed A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 after Repeated Doses in Schizophrenic Patients. Relationship with Pharmacokinetics and Efficacy Readouts.
776423/001 Completed A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age) Study Listed on ClinicalStudyDataRequest.com
782528/902 Completed A six way crossover study to evaluate the impact of dosing of 10 mg vardenafil and 50 mg sildenafil concomitantly with 400 mg gatifloxacin on cardiac conduction for 16 h post-dose in healthy male subjects aged 18 to 64.
792014/001 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule. Study Listed on ClinicalStudyDataRequest.com
792014/002 Completed A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants Study Listed on ClinicalStudyDataRequest.com
792014/003 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule Study Listed on ClinicalStudyDataRequest.com
797620/001 Completed A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
797620/002 Completed A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/003 Completed A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/004 Completed A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
797629/003 Completed A study to assess the effect of food on pharmacokinetics of a rosiglitazone 4 mg and glimepiride 4 mg combination tablet formulation and to compare the pharmacokinetics of rosiglitazone 4 mg and glimepiride 4 mg combination tablet to concomitant dosing of rosiglitazone 4 mg and glimepiride 4 mg ...

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.